And in 14.5-week-old RT2, Hb-egf−/− mutant mice, we observed both a ~30% decrease in the average total tumor load per mouse (tumor burden—Fig. 5B) and a similar decrease in the average number of tumors per mouse (Fig. 5C). This evidence concerns the gene EGF and neoplasm.